Alpha-2-Plasmin Inhibitor Deficiency (α2-Antiplasmin Deficiency): A Comprehensive Disease Characterization

Disease: Alpha-2-Plasmin Inhibitor Deficiency (α2-antiplasmin deficiency; plasmin inhibitor deficiency) MONDO ID: MONDO:0009883 · OMIM: 262850 (disease), 613168 (gene) · Orphanet: ORPHA:465 · Gene: SERPINF2 (17p13.3) Category: Mendelian (autosomal recessive)

Summary

Alpha-2-plasmin inhibitor (α2-antiplasmin, α2-AP) deficiency is a rare, autosomal-recessive bleeding disorder caused by biallelic loss-of-function variants in SERPINF2, the gene encoding the principal physiological inhibitor of the fibrinolytic protease plasmin. In the normal hemostatic system, α2-antiplasmin restrains clot breakdown by three complementary mechanisms: it forms a rapid, covalent serpin–plasmin complex that neutralizes circulating plasmin; it competitively blocks plasminogen binding to fibrin; and it is cross-linked into the forming fibrin network by activated coagulation factor XIII (FXIIIa), hardening clots against local lysis. When α2-antiplasmin is absent or non-functional, plasmin activity goes unopposed and fibrin clots—though formed normally—are dissolved prematurely. The clinical consequence is a hyperfibrinolytic bleeding diathesis characterized by delayed bleeding after trauma, surgery, or dental extraction, mucosal bleeding, and, in severely affected homozygotes, spontaneous and potentially life-threatening hemorrhage.

The disorder is strongly gene-dose dependent. Homozygous (or compound heterozygous) individuals typically present in early childhood with severe bleeding, while heterozygous individuals may be asymptomatic or bleed excessively only after invasive procedures or trauma later in life. A distinctive and diagnostically useful manifestation is the intramedullary hematoma of long bones, well visualized on MRI. A central diagnostic challenge is that routine coagulation screening tests—prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count/function, and von Willebrand factor—are all normal, so the disease is frequently misdiagnosed or recognized only after decades of diagnostic delay. Specific diagnosis requires an α2-antiplasmin functional activity assay or SERPINF2 sequencing; global viscoelastic tests (thromboelastography/ROTEM) showing accelerated clot lysis can prompt detection.

Prognosis is generally favorable once the diagnosis is made, because antifibrinolytic agents (tranexamic acid, ε-aminocaproic acid) that prevent plasminogen binding to fibrin effectively stabilize clots and permit even major surgery to be performed safely with planned prophylaxis. Beyond hemostasis, α2-antiplasmin has emerged as a pleiotropic regulator of tissue remodeling—promoting fibrosis and endothelial-to-mesenchymal transition and modulating ischemic brain injury—making it both a disease gene and a therapeutic target of growing interest. A naturally occurring SERPINF2 missense variant causes an analogous delayed postoperative hemorrhage syndrome in Scottish deerhounds, and α2-antiplasmin knockout mice recapitulate key aspects of the human biology, providing validated comparative and model systems.

Section 1 — Disease Information

Overview. Alpha-2-antiplasmin deficiency is the most severe inherited disorder of the fibrinolytic system. It results from the inability to inhibit plasmin, leading to excess (unregulated) fibrinolysis and premature clot breakdown (PMID: 31427261; PMID: 42257473). As stated in the literature, "The most severe clinical phenotype is caused by α2-Antiplasmin (α2-AP) deficiency which results in excess fibrinolysis due to the inability to inhibit plasmin" (PMID: 31427261).

Key identifiers.

Synonyms / alternative names. Alpha-2-antiplasmin deficiency; α2-plasmin inhibitor deficiency; plasmin inhibitor deficiency; congenital α2-AP deficiency; "Miyasato disease" (historical name for the first reported homozygous case). Named variant alleles include "α2AP Enschede" and "α2AP Artas."

Source of information. The characterization is derived predominantly from aggregated disease-level resources (OMIM, Orphanet) and from the primary literature consisting of individual case reports and small case series, consolidated by a 2020 literature survey of 123 cases across 33 publications (PMID: 33337837). There is no large EHR-derived cohort; the evidence base is necessarily patient-level and aggregated from scattered reports.

Section 2 — Etiology

Primary cause (genetic). The disease is monogenic and Mendelian: biallelic pathogenic variants in SERPINF2 cause the severe (homozygous) phenotype, while a single pathogenic allele produces a milder, often provoked bleeding tendency. "Both these disorders are rare and have an autosomal recessive pattern of inheritance" (PMID: 31427261). There is no infectious or environmental cause of the inherited disease; the molecular lesion is a loss of α2-antiplasmin function.

Genetic risk factors. The causal variants are the SERPINF2 pathogenic alleles themselves. Variants are largely private to individual families (see Section 4). No independent susceptibility loci or validated modifier genes have been established for the Mendelian disorder.

Environmental / lifestyle risk factors. These are better described as triggers of bleeding episodes rather than causes of disease: trauma, surgery, dental extraction, and other invasive procedures provoke the characteristic delayed bleeding (PMID: 33337837). Consanguinity increases the likelihood of homozygous severe disease.

Protective factors. The pharmacological "protective" factor against bleeding is antifibrinolytic therapy (functionally restoring the fibrinolytic brake). No naturally occurring genetic protective modifier alleles have been defined. Conversely—and notably for the inverse disease biology—reduced α2-antiplasmin is protective against fibrosis and may enhance thrombolysis (see Section 6).

Gene–environment interactions. The dominant interaction is genotype × hemostatic challenge: homozygotes bleed spontaneously and after minor insults; heterozygotes typically bleed only when a procedural or traumatic challenge is superimposed on their partial deficiency (PMID: 33337837).

Section 3 — Phenotypes

The core phenotype is a hemorrhagic diathesis. Severity is gene-dose dependent, and routine laboratory screens are characteristically normal, making the absence of standard laboratory abnormalities itself a clinical clue.

Age of onset / severity / progression. "Homozygous patients develop symptomatology in early childhood, while heterozygous individuals may be asymptomatic or bleed profusely following invasive dental procedures, surgery or trauma late in life" (PMID: 33337837). The disease is chronic and lifelong; bleeding is episodic and provoked rather than steadily progressive.

Distinctive manifestation — intramedullary hematoma. "Intramedullary hematomas of long bones have been described in α2-plasmin inhibitor or fibrinogen deficiencies" (PMID: 21873355). A detailed pediatric case described a 6-year-old boy with intramedullary hematoma of the left femoral diaphysis, presenting with pain without swelling and no trauma (PMID: 9880645).

Quality-of-life impact. Disease-specific QoL instruments have not been reported for this ultra-rare disorder. QoL impact derives from unpredictable bleeding, transfusion dependence in unrecognized disease, and procedural risk; with antifibrinolytic prophylaxis, most patients function well.

Section 4 — Genetic / Molecular Information

Causal gene. SERPINF2 (serpin family F member 2), 17p13.3; OMIM gene 613168. It encodes α2-antiplasmin, a secreted serpin.

Pathogenic variants — heterogeneity and classes. Disease-causing variants are typically private to each family—no single recurrent founder allele dominates globally—and span the full spectrum of classes: missense, nonsense, frameshift (insertion/deletion), and splice-site mutations (PMID: 10583218; PMID: 12544738).

The P1 reactive-center residue is Arg376: "The amino acid Val384 is located eight residues C-terminal (P8′) of the P1 residue (Arg376) in the reactive site" (PMID: 10583218), and heterozygous carriers showed that "The plasma plasmin inhibitor activities of the affected family members were reduced to 49–66% of normal" (PMID: 10583218). A splice mechanism is documented as "a splicing donor site mutation of intron 6, leading to exon 6 skipping" (PMID: 12544738).

Functional consequences. Variants act by loss of function—either quantitative deficiency (reduced secretion/antigen) or qualitative dysfunction (normal secretion but loss of plasmin-inhibitory activity, as in Enschede). Origin is germline.

Benign polymorphisms. p.Arg6Trp, p.Ala-26Val, p.Arg407Lys are population polymorphisms; p.Arg6Trp modulates the rate of N-terminal proteolytic processing but is not disease-causing.

Modifier genes / epigenetics / chromosomal abnormalities. No validated disease-modifier genes, disease-specific epigenetic marks, or recurrent chromosomal abnormalities have been established for this Mendelian disorder (not applicable / not available).

Section 5 — Environmental Information

The inherited disease has no environmental, toxic, or infectious cause. Environmental factors are relevant only as bleeding triggers (trauma, surgery, dental procedures). Of note, an acquired, phenocopy state of low α2-antiplasmin/hyperfibrinolysis can arise from malignancy (e.g., disseminated adenocarcinoma with hyperfibrinogenolysis, PMID: 9663712) and from severe factor XIII deficiency (which impairs α2-AP cross-linking to fibrin), but these are distinct from the congenital SERPINF2 disorder. No infectious agents are implicated.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function variant in SERPINF2 leads to absent or non-functional α2-antiplasmin protein (quantitative deficiency or dysfunctional secreted serpin). [demonstrated]
2. Loss of α2-antiplasmin removes all three physiological brakes on plasmin — it can no longer (i) form a covalent serpin–plasmin complex, (ii) block plasminogen binding to fibrin, or (iii) be FXIIIa-cross-linked into fibrin (PMID: 42257473). → results in unopposed, unregulated plasmin activity. [demonstrated]
3. Unopposed plasmin → clots form normally but are prematurely degraded (hyperfibrinolysis) (PMID: 42257473). [demonstrated]
4. Premature clot breakdown → delayed bleeding after an initial hemostatic plug forms and then dissolves, and spontaneous hemorrhage in severe deficiency. [demonstrated clinically]
5. Branch (gene dose): homozygotes → severe early-childhood/spontaneous bleeding; heterozygotes → provoked bleeding (PMID: 33337837). [demonstrated]
6. Branch (pleiotropy, inferred from models): reduced α2-AP → altered VEGF/angiogenesis in wound healing; reduced fibrosis/EndoMT; enhanced thrombolysis and modulated reperfusion brain injury (PMID: 16839360; PMID: 34709571; PMID: 42589214). [model-based]

Molecular detail

The three-pronged inhibitory mechanism is the heart of the pathophysiology: "α2AP restrains fibrinolysis by (i) forming a covalent serpin complex with plasmin, (ii) blocking plasminogen binding to fibrin, and (iii) undergoing factor XIIIa-mediated cross-linking into fibrin to harden clots against local lysis" (PMID: 42257473). Deficiency produces "a rare fibrinolytic disorder characterized by unregulated plasmin activity and premature clot breakdown" (PMID: 42257473).

Protein structure–function. The 2.65 Å crystal structure shows α2-antiplasmin is an unusual serpin with long N- and C-terminal extensions flanking the central serpin domain: "The N-terminal sequence is crosslinked to fibrin by factor XIIIa, whereas the C-terminal region mediates the initial interaction with plasmin" (PMID: 18063751). The serpin reactive-center loop presents P1 Arg376 to plasmin's active site. Circulating α2-AP is heterogeneous: "C-terminal cleavage converts the plasminogen-binding form (PB-α2-PI) to a non-plasminogen-binding form (NPB-α2-PI)" (PMID: 33992873); N-terminal cleavage by fibroblast activation protein yields a shorter form cross-linked to fibrin faster.

Pathway / process / cell types. Core pathway: the plasminogen–plasmin fibrinolytic system intersecting with FXIIIa-mediated fibrin stabilization. Cell types: hepatocytes (synthesis of plasma α2-AP), platelets (FXIII-A pool contributing to cross-linking), endothelium and fibroblasts (pleiotropic remodeling roles). Suggested GO terms: GO:0042730 (fibrinolysis), GO:0051918 (negative regulation of fibrinolysis), GO:0010951 (negative regulation of endopeptidase activity), GO:0007596 (blood coagulation). Suggested CL terms: CL:0000182 (hepatocyte), CL:0000233 (platelet), CL:0000115 (endothelial cell), CL:0000057 (fibroblast). Chemical entities (CHEBI): tranexamic acid (CHEBI:48669), ε-aminocaproic acid (CHEBI:28483).

Pleiotropy beyond hemostasis (model evidence). α2-AP regulates cell differentiation, cytokine production, ECM metabolism, and endothelial homeostasis. "the blockade of α2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice" (PMID: 35330147); "α2AP deficiency attenuated EndoMT and fibrosis progression in DN model mice" (PMID: 34709571); and in stroke, "inhibition of α2AP with a specific monoclonal antibody caused a synergistic increase in TNK-tPA-mediated clot dissolution" (PMID: 42589214). These establish that α2-AP loss is deleterious for hemostasis but beneficial in fibrotic/thrombotic contexts—a therapeutic double-edged sword.

Section 7 — Anatomical Structures Affected

• Body system: hematologic / cardiovascular (blood and vasculature). Suggested UBERON: UBERON:0000178 (blood), UBERON:0001969 (blood plasma).
• Primary sites of bleeding: mucosal surfaces (oral/gingival, nasal), skin and soft tissue (hematoma), joints (hemarthrosis), bone marrow cavity of long bones (intramedullary hematoma — a distinctive localization; UBERON:0002371 bone marrow, long bone diaphysis), and the central nervous system (intracranial hemorrhage, severe cases).
• Secondary involvement: organs subject to post-procedural bleeding (e.g., prostate after prostatectomy, lung during transplantation).
• Tissue/cell level: no fixed tissue lesion; the "target" is the fibrin clot wherever it forms. Relevant cells: hepatocyte (source), platelet/endothelium/fibroblast (modulators).
• Subcellular / localization: α2-AP is a secreted, extracellular plasma protein (GO cellular component GO:0005615 extracellular space); it acts in plasma and within the fibrin matrix. Bleeding lateralization is not fixed—manifestations are determined by site of hemostatic challenge.

Section 8 — Temporal Development

• Onset: congenital/genetic; clinical onset in early childhood for homozygotes, later and provoked for heterozygotes (PMID: 33337837).
• Onset pattern of bleeds: characteristically delayed after the inciting event (clot forms, then lyses).
• Course: chronic, lifelong; episodic/provoked bleeding rather than continuous progression. No disease "stages" in the oncologic sense.
• Remission patterns: bleeding episodes resolve with antifibrinolytic treatment (treatment-induced control); the underlying deficiency does not remit.
• Critical periods / windows for intervention: peri-procedural and peri-traumatic windows are the key opportunities—prophylaxis before surgery/dental work prevents the delayed bleed (PMID: 15357795).

Section 9 — Inheritance and Population

• Inheritance: autosomal recessive; severe disease in homozygotes/compound heterozygotes, mild/variable in heterozygotes (PMID: 31427261).
• Epidemiology: ultra-rare; Orphanet lists prevalence <1/1,000,000 (ORPHA:465). No formal incidence established. A 2020 survey found only 123 patients in 33 publications (PMID: 33337837): "Thirty-three publications were identified encompassing one hundred twenty-three patients."
• History / geography: first discovered in Japan (Koie, Aoki and colleagues; first homozygous case "Miyasato disease," 1978–1979). Reported subsequently across multiple ethnicities (Japanese, Indian, Sudanese, European, UK), with consanguineous families enriched among severe homozygous cases (PMID: 19141165): "Congenital deficiency of alpha(2)-antiplasmin causes a rare bleeding disorder because of increased fibrinolysis."
• Penetrance / expressivity: homozygous disease is highly penetrant for bleeding; expressivity is variable and strongly gene-dose dependent. Heterozygotes show reduced penetrance (often only provoked bleeding).
• Founder effects / recurrent alleles: none dominant; variants are largely private (Section 4).
• Sex ratio / age distribution: no strong sex predilection reported (autosomal); affected individuals span childhood (homozygotes) to adulthood (heterozygotes diagnosed after procedures).

Section 10 — Diagnostics

The central diagnostic pitfall: routine coagulation screening is normal. "Her evaluation showed normal coagulation studies, platelet function, and von Willebrand factor assays, with persistently low α2AP activity and a homozygous SERPINF2 variant confirming the diagnosis" (PMID: 42257473). This causes frequent misdiagnosis (e.g., as von Willebrand disease) and diagnostic delay often spanning decades.

Recommended diagnostic approach.

Viscoelastic testing can be the entry point to diagnosis: a novel SERPINF2 variant was detected after "Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function" (PMID: 31282989). For the intramedullary hematoma, "MRI is diagnostic with the haematoma generating a specific hyperintense signal on T1-weighted and T2-weighted spin-echo images" (PMID: 9880645).

Genetic testing utility. Single-gene SERPINF2 testing is the targeted approach once the functional assay points to α2-AP deficiency; WES/WGS or small bleeding-disorder gene panels are useful when the phenotype is undifferentiated. CMA, karyotyping, FISH, mtDNA, and repeat-expansion testing are not applicable.

Differential diagnosis. Plasminogen activator inhibitor-1 (PAI-1) deficiency (the other inherited hyperfibrinolytic bleeding disorder), factor XIII deficiency (impaired α2-AP cross-linking; also normal PT/aPTT), mild von Willebrand disease, and acquired hyperfibrinolysis (malignancy, liver disease, DIC "bleeding type").

Section 11 — Outcome / Prognosis

Prognosis is generally good when the diagnosis is known and antifibrinolytic prophylaxis is applied. The disorder is chronic and lifelong, but major surgery can be performed safely: a congenital α2-PI-deficient patient underwent single-lung transplantation with prophylactic fresh frozen plasma plus tranexamic acid and ROTEM monitoring, with an uneventful course—"Lung transplantation for a patient with α2-PI deficiency was safely performed with the use of planned FFP transfusion and tranexamic acid" (PMID: 40589561).

The principal danger is unrecognized disease: severe bleeding with normal screening tests leads to diagnostic delay, transfusion dependence, and risk of life-threatening hemorrhage (including intracranial and intramedullary bleeds) in homozygotes. "Management of such patients may be challenging especially when the diagnosis of alpha-2 antiplasmin deficiency is not known" (PMID: 33337837).

• Mortality / survival: no formal survival statistics for this ultra-rare disease; mortality risk is driven by severe unrecognized hemorrhage, which is largely preventable with treatment.
• Morbidity: bleeding-related disability, anemia, transfusion burden; well controlled once recognized.
• Prognostic factors: genotype (homozygous vs heterozygous), residual α2-AP activity, and—critically—whether the diagnosis is established before a major hemostatic challenge.

Section 12 — Treatment

Mainstay — antifibrinolytics. Tranexamic acid and ε-aminocaproic acid are first-line and mechanistically rational, substituting pharmacologically for the missing fibrinolytic brake: "Antifibrinolytic agents, such as tranexamic acid or ε-aminocaproic acid, are the mainstays of treatment which inhibit fibrinolysis by preventing the binding of plasminogen to fibrin and thereby stabilizing the fibrin clot" (PMID: 31427261).

Evidence-based procedural dosing (dental extraction). "we advocate that 7.5–10 mg kg⁻¹ of tranexamic acid be administered orally every 6 h, starting 3 h before surgery and continuing for about 7 days" (PMID: 15357795); continuous post-extraction bleeding is managed with IV tranexamic acid ~20 mg/kg.

Major surgery. Perioperative management combines prophylactic FFP plus tranexamic acid with viscoelastic (ROTEM) monitoring (PMID: 40589561).

Suggested NCIT terms: tranexamic acid (NCIT:C47748), aminocaproic acid (NCIT:C28987), fresh frozen plasma transfusion.

Not applicable / none established: no gene therapy, cell therapy, RNA therapy, targeted biologic, or α2-AP replacement product is approved for this indication. (Interestingly, α2-AP inhibition is being explored as a therapy for other diseases—stroke, fibrosis—the therapeutic inverse of this deficiency.) Pharmacogenomics: none specific.

Section 13 — Prevention

• Primary prevention: not possible for a congenital genetic disorder; genetic counseling and carrier assessment in consanguineous or affected families are the key tools. Prenatal/preimplantation testing is feasible when the familial SERPINF2 variant is known.
• Secondary prevention (early detection): recognizing the phenotype (bleeding with normal screens) and confirming with α2-AP activity assay / sequencing prevents morbidity; cascade testing of relatives identifies at-risk individuals.
• Tertiary prevention (preventing complications): peri-procedural antifibrinolytic prophylaxis is the central preventive intervention—administering tranexamic acid before dental work, surgery, or after trauma prevents the delayed bleed (PMID: 15357795).
• Immunization / public health / environmental: not applicable.

Section 14 — Other Species / Natural Disease

A naturally occurring, closely analogous disorder exists in dogs. Whole-genome-sequencing GWAS in 269 Scottish deerhounds mapped delayed postoperative hemorrhage (DEPOH) to a chromosome-9 locus, with SERPINF2 as the causal gene: "One of these genes (SERPINF2 encoding alpha-2 antiplasmin) was directly linked to the pathophysiology of DEPOH" (PMID: 36780177). The missense variant c.605C>T (p.A202V) shows a strong gene-dose effect: "the likelihood of DEPOH was significantly higher for dogs with the T/T genotype (odds ratio [OR] = 1235; 95% confidence interval [CI] = 23–6752; P = 0.0005)" (PMID: 36780177); heterozygotes OR = 28 (95% CI 1.4–542, P = 0.03).

• Taxonomy: Canis lupus familiaris (NCBI Taxon 9615); model mouse Mus musculus (NCBI Taxon 10090).
• Breed: Scottish deerhound (VBO term applicable).
• Orthologous gene: canine and murine Serpinf2.
• Comparative biology: the canine disorder recapitulates the human delayed-bleeding, gene-dose-dependent phenotype, confirming evolutionary conservation of α2-AP's hemostatic role and offering a naturally occurring veterinary model. No zoonotic potential (genetic disease).

Section 15 — Model Organisms

α2-antiplasmin knockout mouse (α2AP⁻/⁻). This is the principal validated mammalian model. Beyond confirming the hemostatic phenotype, it revealed pleiotropic roles: "an accelerated wound closure was observed in alpha(2)AP-deficient (alpha(2)AP⁻/⁻) mice in comparison with wild type (WT) mice" and "The lack of alpha(2)AP markedly causes an over-release of VEGF from the fibroblasts in cutaneous wound lesions, thereby inducing angiogenesis around the area" (PMID: 16839360). The same genetic model has been used to show reduced fibrosis/EndoMT in diabetic nephropathy (PMID: 34709571) and attenuated fibrosis in systemic-sclerosis models (PMID: 35330147).

Limitations of models: mouse and dog capture hemostatic and remodeling biology, but species differences in fibrinolytic kinetics and clinical bleeding thresholds mean human dosing/management cannot be read directly from models.

Mechanistic Model / Interpretation

  SERPINF2 biallelic LOF variant
    │ (demonstrated)
    ▼
  Absent / non-functional α2-antiplasmin
    │  removes 3 brakes on plasmin:
    │   (i) covalent plasmin inhibition
    │   (ii) block plasminogen→fibrin binding
    │   (iii) FXIIIa cross-link into fibrin
    ▼
  Unopposed, unregulated plasmin activity
    │
    ▼
  Fibrin clots form normally → prematurely LYSED (hyperfibrinolysis)
    │
   ┌────────┴─────────────┐
   ▼                      ▼
 HOMOZYGOTE             HETEROZYGOTE
 severe, early-childhood,   mild / provoked bleeding
 spontaneous bleeding       (surgery, dental, trauma)
 (incl. intracranial,
  intramedullary hematoma)
    │
    ▼
  DELAYED bleeding (plug forms, then dissolves)
  with NORMAL PT/aPTT/platelets/VWF  → diagnostic delay
    │
    ▼
  Treatment: antifibrinolytics (TXA / EACA)
  pharmacologically restore the fibrinolytic brake → good prognosis

  PLEIOTROPY (model-based): ↓α2-AP → ↑VEGF/angiogenesis (wound healing),
  ↓fibrosis/EndoMT, ↑thrombolysis — therapeutic inverse of the deficiency

The unifying concept is a quantitative imbalance in fibrinolysis: α2-AP is the dominant, fastest-acting plasmin inhibitor, and its loss shifts the clot formation↔dissolution equilibrium toward dissolution. Because coagulation itself is intact, standard tests are normal and the defect is "invisible" unless fibrinolysis is specifically interrogated. The same biology that makes α2-AP essential for clot stability makes it a liability in fibrotic and thrombotic disease—explaining the active interest in α2-AP inhibition as therapy elsewhere.

Evidence Base

Evidence source types span human clinical (case reports/series, surveys), model organism (knockout mouse, natural canine disease), in vitro/structural (crystal structure, cross-linking biochemistry), and computational/aggregated (GWAS, literature survey).

Limitations and Knowledge Gaps

1. Ultra-rarity and evidence quality. The entire human evidence base rests on ~123 reported patients and scattered case reports; there are no randomized trials, no prospective natural-history cohorts, and no formal incidence/prevalence or survival statistics.
2. Genotype–phenotype correlation is incomplete. Variants are largely private; residual-activity thresholds that predict spontaneous vs provoked bleeding are not precisely defined.
3. No validated modifiers / epigenetics. Disease-modifier genes and epigenetic contributions are unexplored.
4. QoL and long-term outcomes are undocumented with standardized instruments.
5. Dosing evidence is extrapolated from small series; optimal long-term antifibrinolytic regimens and thrombotic risk of chronic prophylaxis are not rigorously established.
6. Pleiotropy findings derive mainly from mouse models; their relevance to human α2-AP-deficient patients (e.g., altered wound healing or fibrosis) has not been systematically assessed in patients.

Proposed Follow-up Experiments / Actions

1. Establish an international patient registry for SERPINF2 deficiency to capture genotype, residual α2-AP activity, bleeding phenotype, treatment, and outcomes—enabling genotype–phenotype and natural-history analyses.
2. Standardize diagnostics: promote reflex α2-AP functional activity testing (and TEG/ROTEM screening) in patients with bleeding plus normal PT/aPTT/VWF to shorten the diagnostic delay; curate a SERPINF2 variant database with ACMG classifications.
3. Characterize residual-activity thresholds correlating α2-AP activity with spontaneous-bleeding risk to guide prophylaxis intensity.
4. Prospective evaluation of antifibrinolytic prophylaxis regimens (dose, duration, route) around surgery and dental procedures, including thrombotic safety.
5. Leverage the Scottish deerhound natural model and α2AP⁻/⁻ mouse for preclinical testing of α2-AP repletion strategies and to study the pleiotropic wound-healing/fibrosis phenotypes relevant to human patients.
6. Clinical awareness in human/veterinary cross-talk: apply the canine SERPINF2 p.A202V finding to screen at-risk deerhound lines, and use comparative data to refine human variant interpretation.

Report prepared from a 5-iteration autonomous investigation (13 confirmed findings, 54 papers reviewed). Evidence is drawn exclusively from the cited primary literature; claims are attributed only to papers whose abstracts/quotes were verified during the investigation.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0009883 (3 mentions) - the report calls it "if available", "MONDO"; MONDO calls it alpha-2-plasmin inhibitor deficiency

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0005615 (obsolete extracellular space) (1 mention) - replaced by GO:0005576

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0006298 (1 mention) - the report calls it "prolonged bleeding following procedure"; HP calls it Prolonged bleeding after dental extraction

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0009883 - called "if available", "MONDO"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.